Sign in
Not yet taking people in SpainPhase 4

Trabectedin with or without low-dose radiotherapy for advanced sarcoma

Compares trabectedin given with low-dose radiotherapy against trabectedin alone in adults with advanced sarcoma.

Key facts

Who runs it
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Where
Barcelona, Bilbao, Madrid, Oviedo, San Cristóbal de La Laguna, Sevilla, Valencia, and Zaragoza, SpainSee the 13 sites
Registry title
Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma
Status
Not yet recruiting
Phase
Phase 4
People taking part
80 people, planned
Started
1 Sept 2026
Expected to end
2 Sept 2030
Type of study
Interventional
Record updated
18 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 16-75 with advanced soft tissue sarcoma that has spread or cannot be removed by surgery, who have already had at least one chemotherapy. It compares trabectedin with trabectedin plus low-dose radiotherapy.

Age
16-75 years
Sex
All sexes
Disease stage
Soft tissue sarcoma that has spread (metastasis) or is locally advanced, and cannot be treated by surgery. The disease must have grown within the last 6 months and be measurable (RECIST v1.1).
Earlier treatment
Must have had at least 1 and at most 3 earlier lines of chemotherapy (anthracycline-based, unless anthracyclines cannot be used), without trabectedin or lurbinectedin. No earlier radiotherapy that blocks the radiotherapy of this trial.

Main reasons for not taking part

  • Earlier treatment with trabectedin or lurbinectedin
  • Pregnant or breast-feeding women
  • Known HIV infection
  • Uncontrolled bacterial, fungal or viral infection
  • Another cancer in the past, with some exceptions

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Patients must provide written informed consent before the performance of study-specific procedures and must be willing to comply with treatment and follow-up. Informed consent must be obtained before the start of the screening process. Procedures conducted as part of the patient's routine clinical management (e.g. blood count, imaging tests, etc.) and obtained before the signature of informed consent may be used for screening or baseline purposes if these procedures are conducted as specified in the protocol
  • Adequate bone marrow function (hemoglobin ≥ 9g/dL, leukocytes ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, platelets ≥ 100,000/mm3). Patients with estimated creatinine clearance (based on Cockroft and Gault) ≥ 30 ml/min, albumin ≥ 25g/dL, ALT and AST ≤ 2.5 times the ULN, total bilirubin ≤ ULN, CPK ≤ 2.5 times ULN, alkaline phosphatase ≤ 2.5 times the ULN are acceptable. If the increase of alkaline phosphatase is > 2.5 times the ULN, then the alkaline phosphatase liver fraction and/or GGT must be ≤ ULN
  • Men or women of childbearing potential must use an effective method of contraception* before entry into the study throughout the trial treatment and for 6 months after the last dose of trabectedin. Women of childbearing potential must have a negative urine pregnancy test before study entry
  • Normal cardiac function with an LVEF ≥ 50% by echocardiogram or MUGA
  • HBV and HCV serologies must be performed before enrolment. If HbsAg is positive, it is recommended to reject the existence of a replicative phase (HbaAg+, DNA VHB+). If these were positives, the inclusion is not recommended, remaining at investigators' discretion about the preventive treatment with lamivudine. If a potential patient is positive for anti-HCV antibodies, the presence of the virus should be ruled out with a qualitative PCR, or the patient should NOT be included in the study (if a qualitative PCR cannot be performed then the patient will not be able to enter the study)
  • The patient must have a central venous catheter (preferable port-a-cath instead of Peripherally Inserted Central Catheters (PICC) for treatment, required for trabectedin/lurbinectedin administration
  • Age: 16-75 years old
  • Patients must have a diagnosis of STS (excluding GIST, Clear Cell Sarcoma, Alveolar Soft Part Sarcomas (ASPS), Extraskeletal Myxoid Chondrosarcoma, Epithelioid Haemangioendothelioma, Solitary Fibrous Tumors, extraskeletal Ewing sarcoma and other uncommon STS subtypes for which chemotherapy is not usually recommended), with metastasis or locally advanced disease, and not suitable for metastasectomy or surgical resection or not oncologically recommended metastasectomy. A centralized diagnosis will be performed, and the central diagnosis confirmation will be mandatory before enrolment. Therefore, a representative tumor sample (FFPE block) must be available and sent to the central laboratory during the screening period
  • Disease distribution allows meeting with normal tissue constraints of radiation therapy. Radiation oncologists must confirm this point, considering that the dose for extremities and limb girdles will be 45Gy while for non-extremity will be 30Gy
  • Disease progression within 6 months before study entry
  • The patient must have been considered eligible for systemic chemotherapy. Patients should have received at least one line of systemic therapy (anthracycline-based, unless the patient is not a candidate for treatment with anthracyclines), with a maximum of three previous lines for advanced/metastatic disease are allowed if trabectedin/lurbinectedin has not been included
  • Measurable disease, according to RECIST v1.1 criteria
  • Performance status ≤ 1 (ECOG)
  • Adequate respiratory functions: FEV1 > 1L; DLCO > 40% (patients with pulmonary target lesions)

Who cannot take part

  • Previous treatment with trabectedin/lurbinectedin or radiotherapy (this latter just in case the previous radiotherapy treatment does not allow the radiotherapy treatment of this study due to tissue constraints)
  • Liver inclusion in irradiation fields should be avoided; however, partial inclusion is permitted provided that all dose constraints are strictly met
  • History of other neoplastic diseases except for basal cell carcinoma or in situ cervical cancer adequately treated or no evidence of recurrence for more than 5 years after primary tumor treatment
  • Severe pulmonary, cardiovascular (dyspnea > 2 NYHA) or systemic diseases grade 3 or higher on the NCI-CTCAE v5.0 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity
  • Uncontrolled bacterial, mycotic or viral infections
  • Known positive test for infection by human immunodeficiency virus (HIV)
  • Plasma bilirubin > ULN
  • Creatinine clearance <30ml/min
  • Women who are pregnant or breast-feeding
  • Those women who are not intended to follow the contraceptive guidelines outlined in the protocol
  • Psychological, familial, social, or geographic circumstances that limit the patient's ability to comply with the protocol or informed consent
  • Performance status ≥ 2 (ECOG)

Where in Spain

  • Hospital de la Santa Creu i Sant PauBarcelona, SpainNot yet recruiting
  • Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
  • Hospital Universitario BasurtoBilbao, SpainNot yet recruiting
  • Hospital Clínico San CarlosMadrid, SpainNot yet recruiting
  • Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
  • Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
  • Hospital Universitario Fundación Jiménez DíazMadrid, SpainNot yet recruiting
  • Hospital Universitario Central De AsturiasOviedo, SpainNot yet recruiting
  • Hospital Universitario de CanariasSan Cristóbal de La Laguna, SpainNot yet recruiting
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainNot yet recruiting
  • Hospital Clinico Universitario de ValenciaValencia, SpainNot yet recruiting
  • Hospital Universitario Y Politecnico La FeValencia, SpainNot yet recruiting
  • Hospital Universitario Miguel ServetZaragoza, SpainNot yet recruiting

About the trial

What the trial wants to find out

To evaluate efficacy and the Objective Response Rate (ORR) according to RECIST v1.1 criteria.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma
Plain-language title
Trabectedin with or without low-dose radiotherapy for advanced sarcomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
18 September 2026